Showing 61-70 of 9661 results for "".
- IL-23 Inhibitors Associated With Lowest Psoriatic Arthritis Incidence: Studyhttps://practicaldermatology.com/news/il-23-inhibitors-associated-with-lowest-psoriatic-arthritis-incidence-study/2488799/IL-23 Inhibitors Associated With Lowest Psoriatic Arthritis Incidence in Comparative Study Patients with psoriasis treated with interleukin (IL)-23 inhibitors had a lower observed incidence of psoriatic arthritis (PsA) than those receiving Janus kinase (JAK) inhibitors or IL-17 inhibitor
- National Rosacea Society Awards $25,000 for Research on Rosacea Pathogenesis and Treatmenthttps://practicaldermatology.com/news/national-rosacea-society-awards-25000-for-research-on-rosacea-pathogenesis-and-treatment/2488784/The National Rosacea Society (NRS) has awarded two research grants totaling $25,000 to support investigations into the underlying mechanisms of rosacea, including vascular inflammation, immune system interactions, and the potential association between Helicobacter pylori infection and di
- Melanoma Risk Prediction Models Show Moderate Accuracy in Large Australian Cohorthttps://practicaldermatology.com/news/melanoma-risk-prediction-models-show-moderate-accuracy-in-large-australian-cohort/2488770/Six published melanoma risk prediction models demonstrated varying accuracy in identifying individuals who developed melanoma, with most underestimating absolute risk, according to a cohort study published in JAMA Dermatology. Melanoma Risk Prediction Accuracy and Study Findings<
- Study: Acupressure Improves Rosacea Severity, Reduces Inflammatory Biomarkershttps://practicaldermatology.com/news/study-acupressure-improves-rosacea-severity-reduces-inflammatory-biomarkers/2488756/Device-free auricular acupressure improved clinical outcomes and reduced inflammatory biomarkers in patients with rosacea receiving standard first-line treatment, according to findings from a trial published in JAMA Dermatology. The randomized, single-center, sham-controlled, asse
- UCB Launches Wear It Out Campaign to Raise Awareness of HS, Psoriasis, and Psoriatic Arthritishttps://practicaldermatology.com/news/ucb-launches-wear-it-out-campaign-to-raise-awareness-of-hs-psoriasis-and-psoriatic-arthritis/2488727/UCB has launched Wear It Out, a patient-centered awareness initiative designed to address stigma and highlight the everyday challenges experienced by people living with hidradenitis suppurativa (HS), plaque psoriasis, and psoriatic arthritis (PsA). Announced October 13, the program was dev
- Expert Panel Proposes Practical Treatment Algorithm for Pediatric Molluscum Contagiosumhttps://practicaldermatology.com/news/expert-panel-proposes-practical-treatment-algorithm-for-pediatric-molluscum-contagiosum/2488716/A pediatric dermatology expert panel has proposed a practical treatment algorithm for molluscum contagiosum that emphasizes disease severity, family preferences, and shared decision-making. Presented in a 2026 Fall Clinical Dermatology Conference poster, the framework addresses a common, transmis
- Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitishttps://practicaldermatology.com/news/dupilumab-associated-with-lower-atopic-march-risk-in-pediatric-atopic-dermatitis/2488713/Children with atopic dermatitis (AD) who initiated dupilumab had a lower observed risk of developing additional atopic conditions than matched patients treated with systemic corticosteroids, according to a retrospective US claims study presented at the 2026 Fall Clinical Dermatology Conference.</
- Bleeding Events Infrequent Around Procedures in Remibrutinib CSU Trial Analysishttps://practicaldermatology.com/news/bleeding-events-infrequent-around-procedures-in-remibrutinib-csu-trial-analysis/2488707/A post hoc analysis of the phase 3 REMIX-1 and REMIX-2 trials found that bleeding events were uncommon among patients receiving remibrutinib who underwent surgical or invasive procedures. The findings were presented at the 2026 Fall Clinical Dermatology Conference.1 Remibrutinib
- TOGETHER-PsO Biomarker Analysis Examines Ixekizumab and Tirzepatide in Psoriasis With Obesityhttps://practicaldermatology.com/news/together-pso-biomarker-analysis-examines-ixekizumab-and-tirzepatide-in-psoriasis-with-obesity/2488700/A prespecified exploratory analysis of the phase 3b TOGETHER-PsO trial found broader changes in circulating proteins and blood gene expression among adults receiving concomitant ixekizumab (Taltz; Eli Lilly) and tirzepatide (Zepbound; Eli Lilly) than among those receiving ixekizumab alone, accord
- Galderma to Acquire ZO Skin Health for $1.5 Billionhttps://practicaldermatology.com/news/galderma-to-acquire-zo-skin-health-for-15-billion-expanding-physician-dispensed-skincare-portfolio/2488703/Galderma announced an agreement to acquire ZO Skin Health for $1.5 billion, a move it says will expand its dermatological skincare business and strengthen its presence in the physician-dispensed skincare market. According to a company press release, the all-cash transaction will transfer f